MedTrace Logo

Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

NCT00276757 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2014-01-10

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of Langerhans cell histiocytosis, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may be an effective treatment for Langerhans cell histiocytosis.

PURPOSE: This randomized clinical trial is studying combination chemotherapy to see how well it works in treating young patients with Langerhans cell histiocytosis.

Conditions

  • Childhood Langerhans Cell Histiocytosis

Interventions

DRUG

leucovorin calcium

DRUG

methotrexate

DRUG

prednisolone

DRUG

vinblastine sulfate

Sponsors & Collaborators

  • Histiocyte Society

    lead OTHER

Principal Investigators

  • Kenneth L. McClain, MD, PhD · Texas Children's Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Completion
2013-06-30

Countries

  • United States
  • Argentina
  • Austria
  • Canada
  • France
  • Germany
  • Ireland
  • Italy
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276757 on ClinicalTrials.gov